Lonza will invest $521 million to construct a commercial large-scale fill-finish facility at its site in Stein, Switzerland. According to the Swiss contract development manufacturing organization (CDMO) the facility will support  customers across their entire product life cycle. The firm dubbed the facility located on the same campus as Lonza’s existing plant as “flexible” and said that the location will enable the company to make use of existing capabilities, talent, and infrastructure. “There is significant market demand for commercial drug…